Ignite Creation Date:
2024-10-26 @ 3:38 PM
Last Modification Date:
2024-10-26 @ 3:38 PM
Study NCT ID:
NCT06557213
Status:
NOT_YET_RECRUITING
Last Update Posted:
None
First Post:
2024-08-07
Brief Title:
a Cohort Study Gut Microbiota and HCC
Sponsor:
None
Organization:
None
Study Overview
Official Title:
Prediction of Liver Cancer Treatment Response Based on Gut Microbiota a Cohort Study
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To analyze the predictive role of intestinal microbiota in tyrosine kinase inhibitors TKIs combined with immunotherapy response in patients with intermediate and advanced liver cancer
Detailed Description:
This is a prospective observational cohort study Patients with intermediate and advanced hepatocellular carcinoma who meet the enrollment and exclusion criteria are judged to be unresectable after evaluation by professional physicians and are intended to be treated with anti-angiogenic targeted drugs combined with immune checkpoint inhibitors During the treatment according to clinical needs stool and blood samples were taken regularly and the treatment response of patients was judged according to RECIST V11 criteria and the common adverse reactions during treatment were evaluated by the CTCAE50 grading system and the relationship between intestinal microbiota and liver cancer treatment response was analyzed
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None